Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma

References

• Aladzsity I, Kovács M, Semsei A, et al. (2009). Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 33, 1570–1573.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Alsina M, Bensinger W, et al. (2013). Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 11, 11–17.
   PubMed Web of Science ®Google Scholar
• Banu C, Moise A, Arion CV, et al. (2011). Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. J Med Life 4, 264–268.
   PubMedGoogle Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729–733
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A, et al. (2001). Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98, 2992–2998.
   PubMed Web of Science ®Google Scholar
• Cifci S, Yilmaz M, Pehlivan M, et al. (2011). DNA repair genes polymorphisms in multiple myeloma: no association with XRCC1 (Arg399Gln) polymorphism, but the XRCC4 (VNTR in intron 3 and G-1394T) and XPD (Lys751Gln) polymorphisms is associated with the disease in Turkish patients. Hematology 16, 361–367.
   PubMed Web of Science ®Google Scholar
• Cil E, Kumral A, Kanmaz-Ozer M, et al. 2014. Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer. Mol Biol Rep 41, 3091–3097.
   PubMed Web of Science ®Google Scholar
• Cozen W, Gebregziabher M, Conti DV, et al. (2006). Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15, 2285–2291.
   PubMed Web of Science ®Google Scholar
• Dancester CP, Hussain OAN, Jackson WPU. (1959). Clinical features of multiple myeloma. A review of the clinical manifestations and laboratory investigations in 40 cases. Postgrad Med J 35, 662–667.
   PubMedGoogle Scholar
• Dogra S, Khullar G. (2013). Tumor necrosis factor-α antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol 79(Suppl), S35–S46.
   Web of Science ®Google Scholar
• Du J, Yuan ZG, Zhang CY, et al. (2009). Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma. Zhonghau Xue Ye Xeu Za Zhi 30, 649–653.
   PubMedGoogle Scholar
• Du W, Ye W, Chen M, et al. (2013). Association research between polymorphism of IFN-gamma and IL-10, environmental risk factors, and susceptibility to esophageal cancer. Wei Sheng Yan Jiu 42, 770–776.
   PubMedGoogle Scholar
• Duch CR, Figueiredo MS, Ribas C, et al. (2007). Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res 40, 265–267.
   PubMed Web of Science ®Google Scholar
• Durie BG. (1986). Staging and kinetics of multiple myeloma. Semin Oncol 13, 300–309.
   PubMed Web of Science ®Google Scholar
• Elahi MM, Asotra K, Matata BM, Mastana SS. (2009). Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta 1792, 163–172.
   PubMed Web of Science ®Google Scholar
• Gareth JM, Peter JA, Fiona KM, et al. (2005). Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 129, 358–365.
   PubMed Web of Science ®Google Scholar
• Gonullu G, Basturk B, Evrensel T, et al. (2007). Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28, 1728–1733.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Nguyen AN, et al. (2004). Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10, 7540–7546.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Dooley DC, Keeble WW. (1995). Transforming growth factor beta 1 inhibits expression of the gene products for steel factor and its receptor (c-kit). Blood 85, 1769–1780.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. (2004). Advances in biology of multiple myeloma: clinical applications. Blood 104, 607–608.
   PubMed Web of Science ®Google Scholar
• Jiao F, Xu D, Li Q, et al. (2014). Lack of association between -174G>C and -634C>G polymorphisms in interleukin-6 promoter region and lung cancer risk: a meta-analysis. Tumour Biol 35, 5021–5027.
   PubMed Web of Science ®Google Scholar
• Joshua DE. (1988). Biology of multiple myeloma-host-tumour interactions and immune regulation of disease activity. Hematol Oncol 6, 83–88.
   PubMed Web of Science ®Google Scholar
• Kadar K, Kovacs M, Karadi I, et al. (2008). Polymorphism of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res 32, 1499–1504.
   PubMed Web of Science ®Google Scholar
• Karaoglan I, Pehlivan S, Namiduru M, et al. (2009). TNF-alpha, TGF-beta, IL-10, IL-6 and IFN-gamma gene polymorphisms as risk factors for brucellosis. New Microbiol 32, 173–178.
   PubMed Web of Science ®Google Scholar
• Kovacs E. (2010). Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells? Leuk Res 34, 912–916.
   Google Scholar
• Kyrtsonis MC, Repa C, Dedoussis GV, et al. (1998). Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol 15, 124–128.
   PubMed Web of Science ®Google Scholar
• Li X, Yue ZC, Zhang YY, et al. (2008). Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J Clin Lab Anal 22, 164–171.
   PubMed Web of Science ®Google Scholar
• Lodh M, Goswami B, Gupta N, et al. (2012). Assessment of oxidative stress and inflammatory process in patients of multiple myeloma. Indian J Clin Biochem 27, 410–413.
   PubMedGoogle Scholar
• Mandal S, Abebe F, Chaudhary J. (2014). 174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Genet Mol Res 13, 139–151.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Abe M. (2011). TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone 48, 129–134.
   PubMed Web of Science ®Google Scholar
• Mazur G, Bogunia-Kubik K, Wrobel T, et al. (2005). IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol (Lett) 96, 241–246.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215.
   PubMed Web of Science ®Google Scholar
• Neben K, Mytilineos J, Moehler TM, et al. (2002). Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100, 2263–2265.
   PubMed Web of Science ®Google Scholar
• Omrani MD, Taghipour-Bazargani S, Salari-Lak S, Bagheri M. (2009). Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population. Urol Int 83, 329–332.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bruno B, Boccadoro M, Pileri A. (1995). Interferon-gamma in multiple myeloma. Leuk Lymphoma 18, 215–219.
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Menashe I, et al. (2011). Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol 29, 42–46.
   PubMed Web of Science ®Google Scholar
• Stern M, Opelz G, Dohler B, Hess C. (2010). Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood 115, 3960–3965.
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. (2003). Tumor necrosis factor signaling. Cell Death Differ 10, 45–65.
   PubMed Web of Science ®Google Scholar
• Wang H, Gao C, Xu L, et al. (2008). Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China. Cell Mol Immunol 5, 293–298.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang C, Walayat S, et al. (2011). Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol 158, 330–333.
   PubMed Web of Science ®Google Scholar
• Waterston A, Bower M. (2004). TNF and cancer: good or bad? Cancer Therapy 2, 131–148.
   Google Scholar
• Zheng C, Huang D, Liu L, et al. (2001). Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 95, 184–188.
   PubMed Web of Science ®Google Scholar